Tai康 Biologics Announces Board Approval of Licensing Agreement with Major Japanese Pharmaceutical Company for HER2 Biosimilar EG1206A in Japan
NQ Score
87/100
N1 Content Completeness
9
AI Summary (NQ-processed)
Tai康 Biologics has entered into a licensing agreement with a leading Japanese pharmaceutical company for the commercialization of its HER2 biosimilar EG1206A in Japan. The company will handle R&D and manufacturing, while the Japanese partner will manage regulatory submissions and commercialization.
AI Analysis
Frequently Asked Questions
- Q: What is EG1206A developed by Tai康 Biologics?
- A: EG1206A is a biosimilar of Pertuzumab used to treat HER2-positive breast cancer, with streamlined clinical pathways approved by the U.S. FDA and EMA.
- Q: What revenue will Tai康 gain from this deal?
- A: Up to NT$1.32 billion in upfront, milestone, and royalty payments.
- Q: Who handles regulatory approval in Japan?
- A: The Japanese partner will manage PMDA submissions and commercialization.
- Q: What is the development status of EG1206A?
- A: Positive feedback received from FDA and EMA; regulatory dossiers are being prepared.
- Q: How long is the licensing agreement?
- A: The agreement spans 10 years, from June 29, 115 to June 28, 125.